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Abstract
Purpose Normal brain tissue doses have been shown to be
strongly apparatus dependent for multi-target stereotactic
radiosurgery. In this study, we investigated whether inter-
target dose interplay effects across contemporary radiosurgi-
cal treatment platforms are responsible for such an observa-
tion.
Methods For the study, subsets (n = 3, 6, 9, and 12) of a
total of 12 targets were planned at six institutions. Treatment
platforms included the (1) Gamma Knife Perfexion (PFX),
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(2) CyberKnife, (3) Novalis linear accelerator equipped with
a 3.0-mm multi-leaf collimator (MLC), and the (4) Varian
Truebeam flattening-filter-free (FFF) linear accelerator also
equipped with a 2.5 mm MLC. Identical dose–volume con-
straints for the targets and critical structures were applied for
each apparatus. All treatment plans were developed at indi-
vidual centers, and the results were centrally analyzed.
Results We found that dose–volume constraints were satis-
fied by each apparatus with some differences noted in certain
structures such as the lens. The peripheral normal brain tissue
doses were lowest for the PFX and highest for TrueBeam FFF
and CyberKnife treatment plans. Comparing the volumes of
normal brain receiving 12 Gy, TrueBeam FFF, Novalis, and
CyberKnife were 180–290 % higher than PFX. The mean
volume of normal brain-per target receiving 4-Gy increased
by approximately 3.0 cc per target for TrueBeam, 2.7 cc per
target for CyberKnife, 2.0 cc per target for Novalis, and 0.82
cc per target for PFX. The beam-on time was shortest with
the TrueBeam FFF (e.g., 6–9 min at a machine output rate of
1,200 MU/min) and longest for the PFX (e.g., 50–150 mins
at a machine output rate of 350 cGy/min).
Conclusion The volumes of normal brain receiving 4 and 12
Gy were higher, and increased more swiftly per target, for
Linac-based SRS platforms than for PFX. Treatment times
were shortest with TrueBeam FFF.
Keywords Stereotactic radiosurgery · Gamma Knife ·
Intensity modulation · Brain metastases
Introduction
Stereotactic radiosurgery (SRS) is well established as the
treatment of choice for patients presenting with 1–4 brain
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metastases [1,2]. Clinical data are now emerging to support
its role for more than four metastases [3]. This shift in prac-
tice from whole brain radiotherapy (WBRT) is largely due to
rapid technical developments in SRS technology that enables
multiple brain lesions to be treated in a single session [4]. In
order to investigate the potential for SRS technologies to ade-
quately treat multiple targets in the brain, we previously eval-
uated the Gamma Knife Perfexion (Elekta, Atlanta, Georgia),
CyberKnife (Accuray, Sunnyvale, California), and Novalis
(BrainLAB AG, Heinstetten, Germany) treatment platforms
via a multi-center exploratory treatment planning study [5].
In that study, we observed that Perfexion (PFX) yielded the
lowest normal brain tissue doses and the benefits increased
with increasing number of targets.
However, new technologies have since emerged in the
treatment of multiple metastases that require evaluation. The
major advance lies in linac-based systems that allow for
flattening-filter-free (FFF) and intensity-modulated arc beam
delivery. The dominant technology is the TrueBeam FFF
(Varian Oncology, Palo Alto, California) system, which is
capable of modulating the beam intensity, the dose rate, and
the gantry rotation simultaneously during a treatment deliv-
ery [6]. This system has been reported as a valid technol-
ogy in the treatment of multiple metastases targets with a
single or few isocenters with rapid treatment times, and a
recent clinical study demonstrated promising results specific
to the treatment of multiple targets in the brain [7]. Hence, the
purpose of our study was to determine how FFF intensity-
modulated arc beam SRS technology compares dosimetri-
cally in the treatment of multiple brain metastases to the
traditional dynamic conformal arc (DCA) delivery namely
as used in the Novalis SRS system, the CyberKnife, and the
Gamma Knife PFX.
Methods and materials
Following the same multi-institutional study protocol as per
our previous publication, a multiple metastases SRS case
was selected for independent treatment planning using the
Gamma Knife PFX, CyberKnife, Novalis DCA delivery, and
the TrueBeam FFF intensity-modulated arc delivery systems.
An illustration of these modalities is given Fig. 1. In brief,
subsets of target combination with 3, 6, 9, and 12 targets were
selected for treatment planning using individual SRS modal-
ities each housed in different institutions, which were chosen
due to their expertise with the given technology. The spatial
distribution of all the targets is shown in Fig. 2. For a robust
comparison of the new TrueBeam FFF with the previously
studied modalities, two independent institutions were used
for planning with the TrueBeam FFF, each with their own
treatment planning strategies.
Fig. 1 Illustrations of four SRS modalities for the study:
a Gamma Knife Perfexion b Cyberknife c Novalis DCA d Flat-
tening filter free Truebeam. a was courtesy of Elekta (Atlanta, Georgia,
USA)
123
Int J CARS (2014) 9:1079–1086 1081
Fig. 2 Illustration of the brain metasteses case with 12 lesions within
the cranium for the study. All the lesions are 1 cc or less in volume
The dose–volume constraints for the target and the crit-
ical structures are given in Table 1, The planning details
for Gamma Knife Perfexion, Novalis DCA, and CyberKnife
have been described in our previous publication. However,
for Cyberknife treatment planning, standard clinical software
was used in the current study, as opposed to the research
software used in our prior study. The two institutions that
performed TrueBeam FFF treatment planning studies used
their own independent treatment planning approaches. At
one institution, two axial coplanar arcs (one arc rotation fol-
lowed by another one in reverse direction) were employed for
all treatment plans: Arc No 1: 179.9◦–180.1◦ with collimator
at 45◦; Arc No 2: 180.1◦–179.9◦ with collimator set at 315◦.
At the other institution for the 3-, 6-, and 9-target plans, they
used the same approach as above. However, for the 12-target
treatment plan, they added one more arc, duplicating Arc No.
2 as Arc No. 3. All plans were created for a high-definition
MLC with a 2.5 mm central leaf width.
Each treatment plan was centrally analyzed. The dose–
volume parameters for the normal brain as well as other
critical structures were extracted. Comparisons were made
to investigate (1) peripheral normal brain isodose volume
changes for each target combinations and (2) clinical beam-
on time for each modality when delivering these treatment
plans.
Results
All studied SRS modalities satisfied the normal tissue dose
constraints. The lens dose constraint was 2 Gy, and the mean
lens doses were 0.31 (range 0.13–0.49) Gy for PFX, 0.37
(range 0.2–0.54) Gy for Novalis, 1.35 (range 0.86–1.84) Gy
for CyberKnife, and 1.83 (range 1.68–1.98) Gy for True-
Beam FFF. The higher lens doses observed for the Cyberknife
and TrueBeam plans were likely a result of inverse plan-
ning optimization to a 2 Gy lens dose constraint. Figure 3
shows the results of Paddick conformity indices (PCI) [9]
for the four SRS modalities. Note that Truebeam FFF PCI
values were either the highest or the second highest for
all the treatment plans. Among isocentric linac-based SRS
delivery, Truebeam FFF with intensity-modulated arc beams
produced consistently superior PCI values compared with
CyberKnife and Novalis DCA delivery (which exhibited the
lowest PCI values among the studied SRS treatment modal-
ities). Among all the modalities, the central target dose hot
spots such as 120 % of the prescibed dose was highest for PFX
because of the standard practice of selecting a low isodose
value such as 50 % of the maximum dose when prescribing a
treatment.
The treatment beam-on time for each modality is also
plotted in Fig. 4. From the results of Fig. 4, Gamma Knife
PFX produced the longest beam-on time, while Truebeam
FFF produced the shortest beam-on time. Physically, Gamma
Knife PFX delivered treatment at the lowest machine out-
put of 350 cGy/min, while the Truebeam FFF delivery ran at
the highest machine output of 1,200 MU/min. Note that the
machine output for the Gamma Knife PFX also decreases by
approximately 1.1 % per month due to the 60Co decay, and
the reference dose rate for Cyberknife and Novalis was 800
MU/min in Fig. 4. For the 12-target treatment time as shown
in Fig. 4, the treatment time for Cyberknife was found to
reach the same level as that of Gamma Knife PFX. This is
largely due to the a large number of beam angles required for
the Cyberknife cover all the targets simultaneously which in
effect lower its dose rate to be comparable to that of Gamma
Knife PFX in the clinical version of the planning software
[5,8].
Table 1 Dose–volume histogram-based treatment planning constraints for individual targets and the normal structures for this study
Structure name Target PS PG BS ON OC Eyes Lens Ears
Constraint type >99 % Volume Mean dose Mean dose Max dose Max dose Max dose Max dose Max dose Max dose
Dose level ≥20 Gy ≤6 Gy ≤8 Gy ≤10 Gy ≤8 Gy ≤8 Gy ≤6 Gy ≤2 Gy ≤4 Gy
PS pituitary stalk, PG pituitary gland, BS brain stem, ON optical nerve, OC optical chiasm
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Fig. 3 Comparison of Paddick
dose conformity index for
treatment plans with
N = 3, 6, 9, and 12 targets
respectively. The four SRS
modalities are denoted as: GK
Gamma Knife Perfexion, CK
CyberKnife, NOV Novalis, FFF
flattening filter free Truebeam
Fig. 4 Comparison of the
normal beam-on time for
treatment plans with
N = 3, 6, 9, and 12 targets
respectively. The four SRS
modalities are denoted as: GK
Gamma Knife Perfexion, C K
CyberKnife, N OV Novalis,
F F F flattening filter free
Truebeam
The dependence of varying isodose volumes (i.e., from
20-Gy prescription isodose volume to 4-Gy isodose volume)
with increasing number of targets for each SRS modality is
plotted in Figs. 5 (n = 3 vs. n = 6) and 6 (n = 9 vs. n = 12).
Note the logarithmic y-axis for all the plots and nonlinear
dependence in the isodose volumes with increasing number
of targets similar to what was observed in our previous study
[5]. Among the four SRS modalities, Gamma Knife PFX
yielded the lowest 4-Gy isodose volumes while Truebeam
FFF yielded the highest 4-Gy isodose volumes for n = 3, 6, 9
treatment plans, and CyberKnife yielded the highest 4-Gy
isodose volume for n = 12 treatment plans. The difference
in the 4-Gy isodose volumes between the average of these two
modalities, and Gamma Knife PFX is in the range of 200–
300 %. Although the differences among the four modalities
at higher isodose volumes such as the 12-Gy isodose volumes
were narrower, Gamma Knife PFX still resulted in the lowest
12-Gy isodose volumes among all the modalities.
Finally, dose interplay effects, defined as the additional
dose delivered to the normal brain surrounding each target
as a result of irradiating the other targets, were measured in
this study by examining the average peripheral isodose vol-
umes (such as the dose enclosed by the isodose levels at the
20–80 % of the prescribed dose) per target versus increasing
number of targets. Note that such a dose interplay effect was
contributed by the scattering as well as the direct-hit photon
beams. For example, when planning a three-target SRS case,
irradiation of the first target from a large number of beams
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Fig. 5 Semi-logarithmic plot of
normal brain isodose volumes
with N = 3 and N = 6 of
targets for the four SRS
modalities (GK Gamma Knife
Perfexion, C K CyberKnife,
N OV Novalis, F F F flattening
filter free Truebeam)
(e.g., 100–200) inevitably produced a variable dose back-
ground to the second and to the third target. However, when
accounting for such a dose background, dose delivered to the
second or to the third target will in return affect the dose to the
first target in a reciprocal manner. As the number of the tar-
gets increases, such a dose interplay effect was found to vary
among different SRS platforms. The results are illustrated in
Fig. 7. Both the 12-Gy and the 4-Gy isodose volumes were
plotted with increasing number of targets in Fig. 7. A rapid
linear increase in the 4-Gy isodose volume per target, indi-
cating greater interplay effects, was observed for linac-based
modalities as compared to the Gamma Knife PFX. The dip
for the Truebeam FFF curve at n = 12 was from averaging
the results from the two different treatment planning strate-
gies (e.g., averaging the results between the 2-arc technique
and the 3-arc technique), in contrast to those of n = 3-, 6-,
9-target treatment plans where all FFF treatment plans were
created with a 2-arc technique. Significantly higher increase
in the 12-Gy volume per target was also noted for the linac-
based modalities as compared to the PFX, where no depen-
dence in the 12-Gy volume per target with increasing number
of targets was observed. This suggests that interplay effects
significantly increase the 12-Gy peripheral isodose volume
for the linac-based modalities, but less so for the Gamma
Knife PFX.
Discussion
In this study, we report significantly lower normal brain tissue
exposure when treating multiple brain metastases with the
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Fig. 6 Plot of normal brain
isodose volumes with a
relatively high number (N = 9
and N = 12) of targets for the
four SRS modalities (G K
Gamma Knife Perfexion, C K
CyberKnife, N OV Novalis,
F F F flattening filter free
Truebeam)
Gamma Knife Perfexion, as compared to contempory linac-
based SRS modalities including the single-isocenter True-
Beam FFF intensity-modulated arc beam-based SRS system.
Furthermore, we found that dose interplay effects tracked the
trend for these modalities and this is the first report quanti-
fying dose interplay effects for multi-target intracranial SRS
treatments.
Comparison among modalities for multi-target SRS
Based on the dose interplay effect analysis, we observe that
multi-isocenter SRS delivery, such as that implemented by
the Gamma Knife PFX and Novalis DCA, tends to pro-
duce better normal brain tissue sparing as compared to
single-isocentric SRS (TrueBeam FFF) or non-isocentric
SRS (CyberKnife). In addition, the dose interplay effects
were greater at the lower doses, such as the 4-Gy isodose
volume, as compared to the higher doses, such as the 12-Gy
isodose volume. This is expected as the lower-level isodose
volumes tend to be more affected by the scattered radiation
plus entrance and exit dose contributions, as compared to the
higher-level isodose volumes where primary radiation con-
tributions tend to dominate.
With respect to the beam-on times plotted in Fig. 4, these
should be carefully interpreted as their values may grossly
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Fig. 7 Linear plot of average normal brain isodose volumes per target
versus increasing number of targets (N ) for the four SRS modalities
(GK Gamma Knife Perfexion, C K CyberKnife, N OV Novalis, F F F
flattening filter free Truebeam). Note the significantly lower slope gradi-
ent and y-intercept values for the GK as compared with other linac-based
modalities
underestimate the overall effort involved in the actual treat-
ment. For example, little time gap can be expected between
the beam-on time and treatment delivery for Gamma Knife
PFX due to the rigid frame alignment and the known output
rate from the 60Co decay. In comparison, daily output and
potential isocenter variability in linear accelerator-based SRS
mandate stringent patient setup and machine quality assur-
ance efforts to realize this complex treatment (e.g., machine
output verification plus isocenter fidelity checks). In addition,
patient alignment with online or near-real time kV imaging
must be added to the beam-on times reported in Fig. 4.
Significance of current work
Unlike our previous exploratory study, where no clinical
reports exist for using Novalis DCA or Cyberknife SRS
toward multi-target SRS of n > 3 brain metastases, this work
for the first time compared the clinically reported FFF-based
SRS technique against the standard Gamma Knife PFX for
multi-target SRS in a controlled multi-center setting. The
inclusion of Novalis DCA and Cyberknife data was for the
purpose of completion and consistency as well as for com-
posite analysis of the newly proposed dose interplay effects
across all state-of-the-art SRS platforms. From the dose inter-
play analysis, it is evident that minimizing inter-target dose
cross-talk is the key in decreasing the dose to the normal
brain dose for clinical implementation of a new multi-target
SRS technology.
Limitations of the current study include that all of the
planning was performed on a common set of image studies
with limited number of target combinations and distributions.
Note that the 12-studied targets were 1.0 cc or less in volume
and mostly near spherical. The results of the study may not be
applicable for single large or irregularly shaped metastases
as shown in another study [10].
It is worth noting that, as in our previous study [5], we
have confirmed a general trend in the variations of the normal
brain dose among the SRS modalities. We acknowledge that
special modification of the linac-based treatment planning
techniques, such as expanding solid angles of beam access
and/or more beams/arcs, may produce different values than
those shown in Figs. 5 and 6. However, this study used expert
planners familiar with their own SRS technology, so we sur-
mise that extra planning effort would produce relatively small
improvements compared with the large differences observed
due to the SRS technologies themselves.
Clinical relevance and future studies
Theoretically, the greater the radiation exposure of normal
brain, the greater the potential for neurocognitive adverse
effects. Although it has been confirmed in randomized tri-
als that WBRT result in diminished verbal memory scores
and quality of life scores for patients [11–13], the clinical
impact of exposing partial volumes of the normal brain to low
doses of radiation in a single fraction is unknown. Interest-
ingly, a recent study on hippocampal sparing WBRT suggests
less potential for neurocognitive decline. Gondi et al. [14]
reported that a dose of 7.3 Gy2 to 40 % of both hippocampi
represents a threshold for cognitive impairment. The biolog-
ically equivalent single-fraction dose is 2.9 Gy. Therefore,
SRS alone for patients with multiple metastases is likely to
yield better neurocognitive outcomes as it is the most efficient
in sparing the hippocampi by avoiding WBRT altogether. We
also hypothesize that the best sparing of low-dose radiation
exposure to the hippocapi will likely be optimal for Gamma
Knife PFX given that the maximal benefits occur at the low
doses and not at the higher doses.
The other major clinical issue with respect to peripheral
isodose exposure is the risk of radionecrosis. A clinically val-
idated relationship has been reported demonstrating that the
greater the 12 Gy volume, the greater the risk of radionecrosis
[15]. Therefore, it is reasonable to expect that the ability of
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the Gamma Knife PFX to minimize 12-Gy volume in normal
brain may yield lower rates of radionecrosis. This expectation
needs clinical validation in the context of SRS treatments for
multiple brain metastases. On-going clinical trials such as the
randomized study for multiple metastases led by the North
American Gamma Knife Consortium and the MD Anderson
Cancer Centre Phase 3 randomized trial comparing WBRT to
SRS alone for 1–10 metastases may answer these questions.
Conclusion
For the multi-target SRS, Gamma Knife PFX spares the nor-
mal brain tissue best, however, at the expense of longest
beam-on time. Linac-based SRS delivery systems yield
greater dose exposure within the normal brain tissues. Nor-
mal brain exposure per target rises more swiftly with linac-
based technologies than Gamma Knife PFX.
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